ASCO Endorses AUA/ASTRO Treatment Guideline Regarding Radiotherapy After Prostatectomy
the Cancer Therapy Advisor take:
The American Society of Clinical Oncology (ASCO) recently released their endorsement of the American Urological Association (AUA) and American Society for Radiation Oncology (ASTRO) practice guideline regarding adjuvant and salvage radiotherapy after prostatectomy.
The ASTRO and AUA Guideline states that the discussion about adjuvant radiotherapy should be held between a patient and their oncologist after the patient displays adverse pathologic findings at prostatectomy (ie, positive surgical margins, seminal vesicle invasion, extraprostatic extension).
The guideline also stated that oncologists should discuss salvage radiotherapy with their patients with local recurrence or PSA after prostatectomy. The guideline recommends that the discussion of radiotherapy includes an outline of the potential adverse events (both long-term and short-term) as well as the potential for benefit.
The guideline indicates that after the discussion occurs, the decision regarding whether or not the oncology team should administer radiotherapy should be made by both the multidisciplinary team and the patient, with the understanding that there is not one equal rate of risk of recurrence or clinically meaningful disease progression for every patient and the risk-benefit ratio is different for each individual.
By endorsing this guideline ASCO is stating that their panel of experts determined that the guideline is thorough, clear, and based on the most scientifically relevant evidence in this area.
ASCO released endorsement of the AUA/ASTRO practice guideline.
Purpose of this study is to endorse the American Urological Association (AUA)/American Society for Radiation Oncology (ASTRO) guideline on adjuvant and salvage radiotherapy after prostatectomy. The American Society of Clinical Oncology (ASCO) has a policy and set of procedures for endorsing clinical practice guidelines developed by other professional organizations.
The discussion of radiotherapy should include possible short– and long–term adverse effects and potential benefits. The decision to administer radiotherapy should be made by the patient and multidisciplinary treatment team, keeping in mind that not all men are at equal risk of recurrence or clinically meaningful disease progression.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed